Hematology News

ORLANDO, Fla. — Andexanet alfa, a novel agent to reverse the effects of factor Xa inhibitors, demonstrated similar safety and efficacy outcomes to those seen with other reversal agents, according to an interim analysis of the ANNEXA-4 study.

Varicose veins are associated with increased risk for deep vein thrombosis, pulmonary embolism and peripheral artery disease, according to findings published in JAMA.

SALT LAKE CITY — Among patients with severe hemoglobinopathies, greater total body irradiation followed by nonmyeloablative haploidentical allogeneic bone marrow transplant and posttransplant cyclophosphamide appeared associated with decreased graft failure, according to study results presented at the BMT Tandem Meetings.

Approximately one in five patients with cancer will develop venous thromboembolism.

Mental stress and the anticipation of pain decreases microvascular blood flow, which may trigger episodes of vaso-occlusive crisis among patients with sickle cell disease, according to study results presented at American Physiological Society’s Physiological and Pathophysiological Consequences of Sickle Cell Disease conference.

Children with sickle cell anemia who received higher hydroxyurea doses to increase average fetal hemoglobin levels above 20% had fewer hospitalizations than those with levels below 20%, according to results of a prospective observational study published in American Journal of Hematology.

The FDA expanded the approval of ferumoxytol injection to include all eligible adults with iron deficiency anemia who have intolerance to oral iron or do not respond to oral iron.

Patients treated with radioactive iodine for well-differentiated thyroid cancer demonstrated an increased risk for developing acute myeloid leukemia and chronic myeloid leukemia, study data showed.

Results of hematology and chemistry tests performed on blood samples flown for 3 hours on mid-level drones showed that long drone flights of biological samples are feasible.

A 5-year effort to reduce the number of unnecessary blood transfusions across Johns Hopkins Health System led to an annual cost savings of more than $2 million.